Roche Shelves Phase III Huntington's Candidate Tominersen
Follows Independent Committee Data Review
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
You may also be interested in...
Roche’s Q1 update highlighted some key coming drug catalysts and early stage clinical efforts, including those for a potential COVID pill and for targeted cancer vaccines.
Investors during Roche’s first-quarter update 21 April will be looking for guidance on the strong growth of biosimilar competition to its cancer mainstays and how this may be offset by the group’s pipeline.
The company now turns to its next-generation Huntington drug, WVE-003.